Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy.

Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, Fontana RJ.

Aliment Pharmacol Ther. 2019 Jul 15. doi: 10.1111/apt.15413. [Epub ahead of print]

PMID:
31309615
2.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

3.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

4.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.

Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30361170
5.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

6.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH.

J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x.

7.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

8.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. Erratum in: J Clin Invest. 2018 Apr 2;128(4):1708.

9.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

10.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA.

J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.

11.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
12.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5. Erratum in: BMC Cancer. 2019 Apr 18;19(1):366.

13.

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA.

Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.

14.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

15.

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab.

Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD.

J Immunother Cancer. 2017 Mar 6;5:27. doi: 10.1186/s40425-017-0221-x. eCollection 2017.

16.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD.

J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5.

17.

Metastatic Merkel cell carcinoma response to nivolumab.

Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD.

J Immunother Cancer. 2016 Nov 15;4:79. eCollection 2016. Erratum in: J Immunother Cancer. 2017 Mar 6;5:27.

18.

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

Weber JS, Postow M, Lao CD, Schadendorf D.

Oncologist. 2016 Oct;21(10):1230-1240. Epub 2016 Jul 8. Review.

19.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

20.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Neuro Oncol. 2016 Mar;18(3):455-6. doi: 10.1093/neuonc/nov317. Epub 2016 Jan 13. No abstract available.

21.

Implications of age and conditional survival estimates for patients with melanoma.

Banerjee M, Lao CD, Wancata LM, Muenz DG, Haymart MR, Wong SL.

Melanoma Res. 2016 Feb;26(1):77-82. doi: 10.1097/CMR.0000000000000213.

22.

Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.

Scheier BY, Lao CD, Kidwell KM, Redman BG.

JAMA Oncol. 2016 Jan;2(1):136-7. doi: 10.1001/jamaoncol.2015.3664. No abstract available.

PMID:
26401901
23.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR.

Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.

PMID:
26296952
24.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
25.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

26.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
27.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK.

JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096.

28.

NCCN Guidelines implementation in the multidisciplinary Merkel Cell Carcinoma Program at the University of Michigan.

Schwartz JL, Wong SL, McLean SA, Hayman JA, Lao CD, Kozlow JH, Malloy KM, Bradford CR, Frohm ML, Fullen DR, Lowe L, Bichakjian CK.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):434-41. Review.

PMID:
24616547
29.

Ipilimumab and radiation therapy for melanoma brain metastases.

Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD.

Cancer Med. 2013 Dec;2(6):899-906. doi: 10.1002/cam4.140. Epub 2013 Oct 10.

30.

Concurrent whole brain radiotherapy and bortezomib for brain metastasis.

Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG.

Radiat Oncol. 2013 Aug 21;8:204. doi: 10.1186/1748-717X-8-204.

31.

Clinicopathologic features of primary Merkel cell carcinoma: a detailed descriptive analysis of a large contemporary cohort.

Schwartz JL, Bichakjian CK, Lowe L, Griffith KA, Frohm ML, Fullen DR, Hayman JA, Lao CD, Shah KS, McLean SA, Bradford CR, Johnson TM, Wong SL.

Dermatol Surg. 2013 Jul;39(7):1009-16. doi: 10.1111/dsu.12194. Epub 2013 Apr 3.

32.

Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.

Fox MC, Lao CD, Schwartz JL, Frohm ML, Bichakjian CK, Johnson TM.

J Am Acad Dermatol. 2013 Jan;68(1):13.e1-13; quiz 26-8. doi: 10.1016/j.jaad.2012.09.041.

PMID:
23244384
33.

Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.

Fox MC, Lao CD, Schwartz JL, Frohm ML, Bichakjian CK, Johnson TM.

J Am Acad Dermatol. 2013 Jan;68(1):1.e1-9; quiz 10-12. doi: 10.1016/j.jaad.2012.09.040.

PMID:
23244383
34.

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK.

PLoS One. 2012;7(11):e48787. doi: 10.1371/journal.pone.0048787. Epub 2012 Nov 30.

35.

Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.

Bernacki KD, Betz BL, Weigelin HC, Lao CD, Redman BG, Knoepp SM, Roh MH.

Am J Clin Pathol. 2012 Nov;138(5):670-7. doi: 10.1309/AJCPEQJW3PLOOZTC.

PMID:
23086767
36.

Effects of contiguous scars in dermatoscopic evaluation of clinically atypical melanocytic nevi.

Cha HC, Harting M, Cha KB, Ludgate MW, Olsen SH, Zhao L, Lao CD.

J Am Acad Dermatol. 2012 May;66(5):e179-80. doi: 10.1016/j.jaad.2011.05.028. No abstract available.

37.

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK.

Clin Cancer Res. 2012 Feb 15;18(4):1129-37. doi: 10.1158/1078-0432.CCR-11-2488. Epub 2012 Jan 6.

38.

Personalized oncology through integrative high-throughput sequencing: a pilot study.

Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM.

Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.

39.

Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model.

Lao CD, Johnson T, Sondak VK, Lowe L, Kim DS, Zhao L, Naftanel M, Olsen S, Brenner DE.

J Am Acad Dermatol. 2011 Jun;64(6):1188-90. doi: 10.1016/j.jaad.2010.11.029. No abstract available.

40.

Features predicting sentinel lymph node positivity in Merkel cell carcinoma.

Schwartz JL, Griffith KA, Lowe L, Wong SL, McLean SA, Fullen DR, Lao CD, Hayman JA, Bradford CR, Rees RS, Johnson TM, Bichakjian CK.

J Clin Oncol. 2011 Mar 10;29(8):1036-41. doi: 10.1200/JCO.2010.33.4136. Epub 2011 Feb 7.

41.

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

McDonnell K, Betz B, Fullen D, Lao CD.

Pigment Cell Melanoma Res. 2011 Apr;24(2):390-2. doi: 10.1111/j.1755-148X.2010.00822.x. Epub 2011 Jan 13. No abstract available.

42.

Case 19-2008: Merkel-cell carcinoma.

Wong SL, Lao CD, Bichakjian CK.

N Engl J Med. 2008 Oct 9;359(15):1630; author reply 1630-1. No abstract available.

PMID:
18846685
43.

Merkel cell carcinoma: critical review with guidelines for multidisciplinary management.

Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, Wong SL.

Cancer. 2007 Jul 1;110(1):1-12. Review.

44.

Targeting events in melanoma carcinogenesis for the prevention of melanoma.

Lao CD, Demierre MF, Sondak VK.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1559-68. Review.

PMID:
17134361
45.

Dose escalation of a curcuminoid formulation.

Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE.

BMC Complement Altern Med. 2006 Mar 17;6:10.

46.

Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions.

Lao CD, Brenner DE.

Curr Treat Options Oncol. 2004 Oct;5(5):417-26. Review.

PMID:
15341679
47.

Irreversible ototoxicity associated with difluoromethylornithine.

Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG, Viner JL, Spechler SJ, Hawk ET, Brenner DE.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1250-2.

48.

Dysplasia in Barrett esophagus.

Lao CD, Simmons M, Syngal S, Bresalier RS, Fortlage L, Normolle D, Griffith KA, Appelman HD, Brenner DE.

Cancer. 2004 Apr 15;100(8):1622-7.

49.

Cardiac troponin T: a noninvasive marker for heart transplant rejection?

Alexis JD, Lao CD, Selter JG, Courtney MC, Correa DK, Lansman SL, Kushwaha SS, Gass AL.

J Heart Lung Transplant. 1998 Apr;17(4):395-8.

PMID:
9588584

Supplemental Content

Support Center